Myasthenia Gravis (MG)
13
5
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (14)
The AXIS Registry is a 10-year Longitudinal Research Initiative That Captures the Real-world Experiences of People Living With Autoimmune Neurology Conditions. Launching in Myasthenia Gravis (MG), we Plan to Evaluate Expansion to Other Conditions Across Autoimmune Neurology.
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Sexual and Urinary Dysfunctions in Generalized Myasthenia
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Ripertamab for the Treatment of Myasthenia Gravis